Abivax (ABVX) Capital Expenditures (2024 - 2026)

Abivax's Capital Expenditures history runs 3 years deep, the most recent figure standing at -$63220.3 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 36.6% year-over-year to -$63220.3 in Q1 2026; TTM through Mar 2026 was $153941.5, a 75.92% decrease from a year earlier, with the FY2025 full-year figure at $165294.2, down 76.14% from the prior year.
• Capital Expenditures retreated to -$63220.3 in Q1 2026 per ABVX's latest filing, from $229316.6 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.3 million in Q4 2024 and bottomed at -$341546.3 in Q3 2024.
• The 3-year median for Capital Expenditures is -$21507.2 (2025), against an average of $86697.3.
• Biggest YoY gain for Capital Expenditures was 102.74% in 2025; the steepest drop was 255.03% in 2025.
• Year by year, Capital Expenditures stood at $1.3 million in 2024, then slumped by 81.92% to $229316.6 in 2025, then tumbled by 127.57% to -$63220.3 in 2026.
• Per Business Quant, the three latest ABVX Capital Expenditures figures stand at -$63220.3 (Q1 2026), $229316.6 (Q4 2025), and $9352.4 (Q3 2025).